2025
A generative deep learning approach to de novo antibiotic design. Krishnan A, Anahtar MN, Valeri JA, Jin W, Donghia NM, Sieben L, Luttens A, Zhang Y, Modaresi SM, Hennes A, Fromer J, Bandyopadhyay P, Chen JC, Rehman D, Desai R, Edwards P, Lach RS, Aschtgen MS, Gaborieau M, Gaetani M, Palace SG, Omori S, Khonde L, Moroz YS, Blough B, Jin C, Loh E, Grad YH, Saei AA, Coley CW, Wong F, Collins JJ. Cell. 2025 Aug 7:S0092-8674(25)00855-4. doi: 10.1016/j.cell.2025.07.033. PMID: 40816267
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’. Peuget S, Selivanova G. Nat Rev Cancer. 2025 Jul;25(7):564-565. doi: 10.1038/s41568-025-00825-8. PMID: 40379969
2024
Translating p53-based therapies for cancer into the clinic. Peuget S, Zhou X, Selivanova G. Nat Rev Cancer. 2024 Mar;24(3):192-215. doi: 10.1038/s41568-023-00658-3. PMID: 38287107
2023
Strategies to Isolate Extracellular Vesicles from Gram-Negative and Gram-Positive Bacteria. Narciso AR, Aschtgen MS. Methods Mol Biol. 2023;2674:61-70. doi: 10.1007/978-1-0716-3243-7_4. PMID: 37258960
MDM2-PROTAC versus MDM2 Inhibitors: Beyond p53 Reactivation. Peuget S, Selivanova G. Cancer Discov. 2023 May 4;13(5):1043-1045. doi: 10.1158/2159-8290.CD-23-0229. PMID: 37139722
2022
Enterobacteria impair host p53 tumor suppressor activity through mRNA destabilization. Aschtgen MS, Fragkoulis K, Sanz G, Normark S, Selivanova G, Henriques-Normark B, Peuget S. Oncogene. 2022 Apr;41(15):2173-2186. doi: 10.1038/s41388-022-02238-5. PMID: 35197571